Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL).

MLA

Berrou, Jeannig, et al. “Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL).” Journal of Clinical Medicine, vol. 11, no. 22, Nov. 2022, p. 6761. EBSCOhost, https://doi.org/10.3390/jcm11226761.

APA

Berrou, J., Dupont, M., Djamai, H., Adicéam, E., Parietti, V., Kaci, A., Clappier, E., Cayuela, J.-M., Baruchel, A., Paublant, F., Prudent, R., Ghysdael, J., Gardin, C., Dombret, H., & Braun, T. (2022). Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL). Journal of Clinical Medicine, 11(22), 6761. https://doi.org/10.3390/jcm11226761

Chicago

Berrou, Jeannig, Mélanie Dupont, Hanane Djamai, Emilie Adicéam, Véronique Parietti, Anna Kaci, Emmanuelle Clappier, et al. 2022. “Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL).” Journal of Clinical Medicine 11 (22): 6761. doi:10.3390/jcm11226761.